# Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

> **NCT04142242** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 471 (actual)

## Conditions studied

- Meningococcal Infection (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
- **OTHER:** Blood sample

## Key facts

- **NCT ID:** NCT04142242
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-04
- **Primary completion:** 2020-04-01
- **Final completion:** 2022-05-25
- **Target enrollment:** 471 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04142242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04142242, "Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04142242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*